Evidence map›Paper›PMID 35371004›Full record

ArticleFrontiers in immunology2022

Enterogenous Microbiotic Markers in the Differential Diagnosis of Crohn's Disease and Intestinal Tuberculosis.

Mingshan Jiang, Zhen Zeng, Kexin Chen, Yuan Dang, Lili Li, Chunxiang Ma, Rui Cheng, Kehan Hu, Xi Li, Hu Zhang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Gut microbes · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Precision medicine in inflammatory bowel disease.Precision clinical medicine · 2023
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Mingshan JiangDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
Zhen ZengDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
Kexin ChenDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
Yuan DangDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
Lili LiDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
Chunxiang MaDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
Rui ChengDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
Kehan HuDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
Xi LiDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
Hu ZhangDepartment of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
West China Hospital of Sichuan University · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Crohn's disease (CD) is a chronic intestinal disorder characterized by refractory gastrointestinal ulcerations. Intestinal tuberculosis (ITB) is one common intestinal disease in east Asia. The two diseases share similar clinical manifestations and endoscopic characteristics. Thus, it is difficult to establish a definite diagnosis of CD, CD concomitant with ITB (CD-ITB), and ITB in practice. Some enterogeneous microbiotic markers have been applied to differentiate CD and ITB, but it remains unknown how they work for the three groups of patients. The aim of our study was to explore the diagnostic values of these enterogeneous microbiotic markers (ASCA IgG, ASCA IgA, ACCA, Anti-I2 and AMCA) among CD, CD-ITB, and ITB patients. A total of 124 individuals were retrospectively enrolled in this study, namely, 103 CD patients, 10 CD-ITB patients, 9 ITB patients, and 68 healthy controls. The demographic and clinical characteristics of these patients were collected and analyzed. The values of these individual or combined enterogeneous microbiotic markers in diagnosis and classification were assessed in CD, CD-ITB, and ITB patients. ASCA IgG, ASCA IgA, and AMCA could accurately differentiate CD patients from healthy controls with an area under curve (AUC) of 0.688, 0.601, and 0.638, respectively. ASCA IgG was significantly higher in CD patients than in CD-ITB patients (P = 0.0003). The Anti-I2 antibody was appropriate for distinguishing CD-ITB from ITB patients (P = 0.039). In CD patients, ASCA IgG was higher in severe patients than in mild (P <0.0001) and inactive patients (P <0.0001), respectively. AMCA was significantly elevated in severe and moderate patients compared to inactive patients (P = 0.001, P = 0.003, respectively). AMCA was associated with a higher risk of CD-related surgery with a significant P-value of 0.0038. In our cohort, ASCAs and AMCA could accurately distinguish CD from healthy controls with an acceptable AUC. A combination of elevated ASCA IgG and AMCA antibodies established a higher sensitivity in differentiating CD from healthy controls. Elevated ASCA IgG demonstrated a differential diagnostic value between CD and CD-ITB. Anti-I2 could also distinguish CD-ITB from ITB. The level of AMCA was associated with both disease severity and CD-related surgery. Likewise, the level of ASCA IgG was also related to disease severity.

Indexed as

Crohn DiseaseEnteritisTranexamic AcidTuberculosis, GastrointestinalBiomarkersDiagnosis, DifferentialHumansImmunoglobulin AImmunoglobulin GRetrospective StudiesBiomarkersImmunoglobulin AImmunoglobulin GTranexamic AcidCrohn’s diseasediagnosisdifferential diagnosisenterogeneous microbiotic markersintestinal tuberculosis

Identifiers

PMID35371004
PMCPMC8966387
OpenAlexW4220764766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.